Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis
British Journal of Pharmacology2013Vol. 170(2), pp. 341–351
Citations Over TimeTop 10% of 2013 papers
Masashi Takata, Hirotaka Tanaka, Masahiko Kimura, Yuki Nagahara, Y. Tanaka, Koh Kawasaki, M Seto, Kazuhiro Tsuruma, Masamitsu Shimazawa, Hideaki Hara
Abstract
These findings indicate that fasudil may be effective at suppressing motor neuron degeneration and symptom progression in ALS. Hence, fasudil may have potential as a therapeutic agent for ALS treatment.
Related Papers
- → A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat(2002)111 cited
- → Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in Mice(2003)86 cited
- → Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma(2018)53 cited
- Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in Mice(2004)
- Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats(2007)